中文名 | Rigosertib (sodium) |
英文名 | Rigosertib (sodium) |
别名 | 瑞格色替钠 化合物RIGOSERTIB PLK1抑制剂(RIGOSERTIB SODIUM) |
英文别名 | Novonex ON 01910 Na ON 01910 sodium RIGOSERTIB SODIUM Rigosertib (sodium) RIGOSERTIB SODIUM (ON-01910 SODIUM) (E)-2,4,6-Trimethoxystyryl 3-[(carboxymethyl)amino]-4-methoxybenzyl sulfone sodium salt Glycine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-, sodiuM Slat |
CAS | 592542-60-4 |
化学式 | C21H24NNaO8S |
分子量 | 473.47193 |
熔点 | 174-178℃ |
溶解度 | 溶于DMSO |
存储条件 | -20℃ |
产品用途 | Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM. |
参考资料 展开查看 | 1. Xu F, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signalingtransduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014 Dec 4;4:7310.2. Hyoda T, et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci. 2015 Mar;106(3):287-93.3. Gumireddy K, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005 Mar;7(3):275-86.4. Reddy MV, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.112 ml | 10.56 ml | 21.121 ml |
5 mM | 0.422 ml | 2.112 ml | 4.224 ml |
10 mM | 0.211 ml | 1.056 ml | 2.112 ml |
5 mM | 0.042 ml | 0.211 ml | 0.422 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!